A TÁVOLI ÁTTÉTES KOLOREKTÁLIS RÁK (MCRC) ELSŐ VÁLASZTÁSÚ KEZELÉSÉNEK FEJLŐDÉSE

作者: László Landherr , Tamás Nagykálnai

DOI: 10.1556/MONKOL.53.2009.3.1

关键词:

摘要: Absztrakt A tavoli attetes, IV. stadiumu kolorektalis rak (metastatic colorectal cancer, mCRC) gyogyszeres kezelese jelentős fejlődesen ment at az utobbi evekben. standard fluorouracil/folinat-kezelesek mellett uj hatoanyagok jelentek meg (oxaliplatin, irinotecan), de legujabban a “celzott” biologiai terapias szerek (bevacizumab, cetuximab, panitumumab) is bizonyitottak hatekonysagukat. kozlemeny osszefoglalja mCRC első valasztasu kezelesenek fejlődeset.

参考文章(58)
A. de Gramont, Emmanuel Van Cutsem, J. Sastre, A. Cervantes, J. Van Laethem, Yves Humblet, E. Casac, A. Zubel, N. Gascon, Thibaut André, Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study Ejc Supplements. ,vol. 3, pp. 181- 182 ,(2005)
J Tol, M Koopman, NF Antonini, H Sinnige, FAA Valster, JJ Braun, AJ ten Tije, L Mol, JHJM van Krieken, C Punt, Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) Journal of Clinical Oncology. ,vol. 26, ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.LBA4011
D. Hollis, S. Sutherland, R. Goldberg, S. Alberts, A. Benson, J. Wade, R. Schilsky, R. Mayer, A. Venook, D. Niedzwiecki, Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results Journal of Clinical Oncology. ,vol. 24, pp. 3509- 3509 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.3509
Emel Yaman, Aytug Uner, Ozlem Er, Ugur Coskun, Suleyman Buyukberber, Mustafa Dikilitas, Mevlude Polat, Deniz Yamac, Ali Osman Kaya, Ramazan Yildiz, Banu Ozturk, Mustafa Benekli, , Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer Medical Oncology. ,vol. 24, pp. 431- 435 ,(2007) , 10.1007/S12032-007-0035-7
Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter, Bart Biesmans, Wendy De Roock, An Capoen, Maria Debiec-Rychter, Jean-Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab : A fluorescent in situ hybridization study Clinical Cancer Research. ,vol. 14, pp. 5869- 5876 ,(2008) , 10.1158/1078-0432.CCR-08-0449
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
M Saunders, T Iveson, Management of advanced colorectal cancer: state of the art. British Journal of Cancer. ,vol. 95, pp. 131- 138 ,(2006) , 10.1038/SJ.BJC.6603233
Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, Norbert Niederle, Kurt Possinger, Roberto Labianca, Matilde Navarro, Rudolf Morant, Harry Bleiberg, Jacques Wils, Lucile Awad, Patrice Herait, Christian Jacques, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer The Lancet. ,vol. 352, pp. 1407- 1412 ,(1998) , 10.1016/S0140-6736(98)03085-2
Roberto Petrioli, Loretta Paolelli, Stefania Marsili, Serenella Civitelli, Edoardo Francini, Tommaso Cioppa, Franco Roviello, Raffaele Nettuno, Chiara Intrivici, Gabriello Tanzini, Marco Lorenzi, Guido Francini, FOLFOX-4 Stop and Go and Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer Oncology. ,vol. 70, pp. 345- 350 ,(2006) , 10.1159/000098107